Gabapentin Treatment of Cannabis Dependence

The Scripps Research Institute

Status and phase: Completed; Phase 2

Conditions: Cannabis Dependence

Treatments: Drug: Gabapentin; Drug: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00395044

DA020766-01

5R21DA020766-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This is a study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.

Full description

This is a 12-week, double blind, placebo controlled, dose ranging study to evaluate the efficacy of gabapentin in treating outpatients with cannabis dependence. Counseling and research assessments occur weekly throughout the 12-week treatment phase.

Enrollment: 50 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females age 18-65 with cannabis dependence
• Meets DSM-IV-TR criteria for Cannabis Dependence
• Smoked marijuana at least once a week in the 90 days prior to study participation
• Willing to attend 12 weekly study visits and 1 follow-up visit

Exclusion criteria

• Currently meets DSM-IV-TR criteria for dependence on illicit substances other than cannabis
• Significant medical disorders that will increase potential risk or interfere with study participation
• Women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control
• Treatment with an investigational drug in the last month

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

50 participants in 2 patient groups, including a placebo group

Gabapentin

Experimental group

Description:

1200 mg/daily of Gabapentin

Treatment:

Drug: Gabapentin

Placebo

Placebo Comparator group

Description:

1200mg/d of Placebo

Treatment:

Drug: Placebo